Given the heterogeneity of breast cancer and the fact that cancer treatment may require long-term administration of certain autophagy modulators [60], CLDN6 may act as a biomarker to monitor the autophagy status in vivo. This evidence concerns the gene CLDN6 and breast carcinoma.